# US 2015/0104406 A1 · Metap-2 inhibitor polymersomes for therapeutic administration

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104406 A1
- Document ID: US20150104406A1
- Status: Published application
- Kind: A1
- Application number: 14/495,725
- Filed: 2014-09-24
- Published: 2015-04-16
- Earliest claimed: 2007-06-26
- Assignees: Children's Medical Center Corporation
- Applicants: Children's Medical Center Corporation
- Inventors: Ofra Benny-Ratsaby; Robert D'Amato; Judah Folkman
- Web page: https://patentgrep.com/patent/US20150104406A1

## CPC

- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)}
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 31/336: having three-membered rings, e.g. oxirane, fumagillin
- A61K 47/593: {Polyesters, e.g. PLGA or polylactide-co-glycolide}
- A61K 47/6907: {the form being a microemulsion, nanoemulsion or micelle}
- A61K 47/6915: {the form being a liposome with polymerisable or polymerized bilayer-forming substances, e.g. polymersomes}
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/14: of the thyroid hormones, e.g. T3, T4
- A61P 7/10: Antioedematous agents; Diuretics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61P 31/22: for herpes viruses
- A61P 33/06: Antimalarials
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C01B 32/164: involving continuous processes
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C01B: NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; {METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C}
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Described herein are MetAP-2 inhibitors and compositions and formulations thereof, and more particularly compositions and formulations of MetAP-2 inhibitors wherein the MetAP-2 inhibitor is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety. The present invention also relates to compositions and formulations comprising MetAP-2 inhibitors for oral administration or administration via routes such as topical or ocular administration. The present invention also provides methods to treat conditions associated with or related to the over-expression or over-activity of MetAP-2 by administering the compositions and formulations comprising MetAP-2 inhibitors as disclosed herein.

## Claims

### Claim 1

A composition comprising a methionine aminopeptidase-2 (MetAP-2) inhibitor formulation having anti-proliferative activity, wherein said formulation comprises a MetAP-2 inhibitor covalently linked to a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety.

### Claim 2 (depends on 1)

The composition of claim 1, wherein said MetAP-2 inhibitor is a fumagillol derivative.

### Claim 3 (depends on 1)

The composition of claim 1, wherein said MetAP-2 inhibitor is covalently linked with the hydrophobic moiety of said block copolymer.

### Claim 4 (depends on 1)

The composition of claim 1, wherein said hydrophobic polymer moiety of said block copolymer is selected from the group consisting of poly(d,L-lactic acid), poly(caprolactone) (PCL), and poly(propylene oxide).

### Claim 5 (depends on 1)

The composition of claim 1, wherein said hydrophilic moiety is a poly(ethylene glycol) (PEG) polymer.

### Claim 6 (depends on 1)

The composition of claim 1, wherein said block copolymer is a diblock copolymer comprising a PEG-PLA diblock copolymer having hydrophilic PEG and hydrophobic PLA moieties.

### Claim 7

A method of treating a condition involving or relying upon MetAP-2 activity for its pathology, the method comprising administering a MetAP-2 inhibitor formulation comprising a MetAP-2 inhibitor having anti-proliferative activity, covalently linked to a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety.

### Claim 8 (depends on 7)

The method of claim 7, wherein said MetAP-2 inhibitor is a fumagillol derivative.

### Claim 9 (depends on 7)

The method of claim 7, wherein said MetAP-2 inhibitor is associated with the hydrophobic moiety of said block copolymer.

### Claim 10 (depends on 7)

The method of claim 7, wherein said hydrophobic polymer moiety of said block copolymer is selected from the group consisting of poly(d,L-lactic acid), poly(caprolactone) (PCL), poly(propylene oxide).

### Claim 11 (depends on 7)

The method of claim 7, wherein said hydrophilic moiety is a poly(ethylene glycol) (PEG) polymer.

### Claim 12 (depends on 7)

The method of claim 7, wherein said block copolymer is a diblock copolymer comprising a PEG-PLA diblock copolymer having hydrophilic PEG and hydrophobic PLA moieties.

### Claim 13 (depends on 7)

The method of claim 7, wherein said anti-proliferative composition has anti-tumor activity.

### Claim 14

A method of making a diblock copolymer composition comprising a MetAP-2 inhibitor that has anti-proliferative activity, the method comprising conjugating said MetAP-2 inhibitor to a diblock copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety.

### Claim 15 (depends on 14)

The method of claim 14, wherein said MetAP-2 inhibitor is a fumagillol derivative that has anti-angiogenic activity.

### Claim 16 (depends on 14)

The method of claim 14, wherein said MetAP-2 inhibitor comprises 6-O—(N-chloroacetylcarbamoyl) fumagillol (TNP-470).

### Claim 17 (depends on 14)

A diblock copolymer composition comprising a MetAP-2 inhibitor, said composition produced by the method of claim 14.

### Claim 18 (depends on 17)

The diblock copolymer composition of claim 17, wherein said MetAP-2 inhibitor is a fumagillol derivative that has anti-proliferative activity.

### Claim 19 (depends on 17)

The diblock copolymer composition of claim 17, wherein said fumagillol derivative comprises 6-O—(N-chloroacetylcarbamoyl)fumagillol (TNP-470).
